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Abstract 
The ability to identify key biomolecules and molecular changes associated with cancer malignancy and the capacity 
to monitor the therapeutic outcome against these targets is critically important for cancer treatment. Recent develop-
ments in molecular imaging based on magnetic resonance (MR) techniques have provided researchers and clinicians 
with new tools to improve most facets of cancer care. Molecular imaging is broadly described as imaging techniques 
used to detect molecular signature at the cellular and gene expression levels. This article reviews both established 
and emerging molecular MR techniques in oncology and discusses the potential of these techniques in improving 
the clinical cancer care. It also discusses how molecular MR, in conjunction with other structural and functional MR 
imaging techniques, paves the way for developing tailored treatment strategies to enhance cancer care.
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Background
Advancement in understanding of molecular and cellu-
lar processes in cancer led to the development of various 
imaging based techniques, which can monitor these pro-
cesses non-invasively in vivo and provide opportunity to 
better describe cancer biology, and to assess therapeutic 
targets. Imaging techniques which target these molecu-
lar and cellular physiologies are grouped under a broad 
term “molecular imaging”. Molecular imaging provides a 
new approach to image and characterize the key biomol-
ecules and molecular changes associated with the cancer 
malignancy [1]. Molecular Imaging offers non-invasive 
and repetitive detection of cancer cellular-biochemistry 
and physiology in  vivo, which may help to predict the 
tumor response against a specific treatment and may pro-
vide more definite criteria for patient selection to identify 
those that would respond to treatment.
Various imaging modalities including single photon 
emission computed tomography (SPECT), positron 
emission tomography (PET), optical imaging, magnetic 
resonance imaging (MRI), and magnetic resonance spec-
troscopy (MRS) have been widely used to monitor struc-
tural, functional, and molecular changes in cancer tissues 
both clinically and pre-clinically [2–12]. PET and SPECT 
use radiotracers to image and measure the biological 
activity at targeted site, and are generally considered as 
molecular imaging modalities. However, despite exqui-
site sensitivity they are beset by poor resolution and the 
application of nuclear radiation may preclude their use 
for repetitive measurements in a short time period. Opti-
cal imaging has been used to image specific molecular 
features of cancer by employing molecular targeted con-
trast agents [7, 13]. Studies have suggested that optical 
based method can provide early information of treatment 
efficacy [14, 15]. However, requirement of the optical 
probe insertion in tissue limits its repetitive use, and also 
it is not suitable for studying parts of tissue that are dis-
tant from the probe.
Due to its non-invasive characteristics and high spatial 
resolution, MRI is one of the most powerful imaging tools 
available in diagnostic imaging, and has been readily used 
in preclinical research studies too. Recent development of 
new MR methods, which focus on imaging of molecular 
signatures, and development of novel molecular contrast 
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agents have expanded the strength of MRI in character-
izing tissue physiological and molecular changes. In this 
review article, we outline different molecular MR imag-
ing techniques describing cellular and molecular changes 




Altered cellular metabolism is key for cancer growth 
and malignancy [16, 17]. Many of the biochemical path-
ways particularly, glycolysis, pentose phosphate pathway 
(PPP), and TCA cycle are subjected to alternative regula-
tion in cancer cells [18–23]. Monitoring and understand-
ing the cancer metabolism in  vivo drastically improves 
diagnosis and treatment planning of cancer. It was Otto 
Warburg who demonstrated high glucose consumption 
and lactate production in cancer compared to healthy tis-
sues and conceptualized that tumor metabolism differs 
from that of normal tissue [24, 25]. This pivotal observa-
tion created a field of tumor metabolism, and led to the 
development of different MR techniques to monitor met-
abolic changes in cancer tissues in vivo.
Magnetic resonance spectroscopy (MRS)
Magnetic resonance spectroscopy has been widely used 
to detect metabolic changes in cancerous as well as in 
normal tissues [26]. Different metabolic markers, detect-
able by MRS, not only provide information on bio-
chemical changes in response to tumor growth but also 
delineate different metabolic tumor phenotypes. Proton 
MRS (1H MRS) is widely used MRS method to monitor 
metabolic changes in cancer tissue [27–32]. The other 
active nuclei such as, 31P (phosphorus), 13C (carbon) and 
19F (fluorine) are also being used to monitor bioenerget-
ics and metabolic flux in cancer [33–46].
1H MRS is most commonly used method to detect met-
abolic changes in cancer tissues [27–32]. The 1H signal 
from total choline (Cho) is significantly elevated in can-
cer tissue, which is shown to be correlated with cellular 
proliferation in cancer [47–50]. Choline ratios with other 
metabolites are routinely used to classify cancer aggres-
siveness. For example- Cho/(N-acetylaspartate  (NAA)) 
ratio is used to distinguish low and high grade astrocy-
toma’s and gliomas [51], while Cho/(creatine) Cr is used 
to differentiate low grade glioma from benign lesion [52]. 
It has been shown that distinct patterns of Cho metabo-
lism are associated with different gene expression profiles 
in the luminal and basal like breast cancers xenograft 
models [53], and the serial choline levels measured by 
MRS provide an early indicator of treatment response 
in the breast cancer [54]. Alteration in the profile of 
choline compounds is associated with the malignant 
transformation of breast, and ovarian cancers [55–57]. 
Both breast and ovarian cancer cells showed higher phos-
phocholine (PC) signal while glycero-PC (GPC) signal 
was predominant in nonmalignant breast and ovarian 
epithelial cells [56, 58]. Not only 1H MRS but 31P MRS 
also has been used to detect the changes in choline 
metabolites such as phosphomonoesters, and phosphodi-
esters in cancer, which has been proven valuable in moni-
toring response of tumors to anti-cancer therapy.
Magnetic resonance spectroscopic imaging (MRSI) 
provides spatial mapping of endogenous metabolites and 
thus can provide heterogeneous distribution of these 
metabolites in cancer tissue [59, 60]. The spatial map-
ping of Cho proton signal can reveal aggressive areas in 
tumor tissue and help to monitor therapeutic responses 
[61, 62]. In vivo MRSI improves diagnostic specificity of 
malignant human cancers and is becoming an important 
clinical tool for cancer’s management and care [63].
31P MRS, in spite of its lower sensitivity provides 
important information about cancer metabolism. 31P 
MRS detects metabolites such as phosphocreatine (PCr), 
nucleotide triphosphate (NTP), phosphomonoesters 
(PME), phosphodiesters (PDE) and inorganic phosphate 
(Pi) [64]. Phosphomonoesters include phosphocho-
line, phosphoethanolamine and phosphoserine, while 
phosphodiesters include glycerylphosphocholine, glyc-
erophosphoethanolamine and glycerylphosphoserine. 
In breast cancer, 31P MRS showed increased concentra-
tion of PME compared to normal breast tissue [65] and 
following chemotherapy a decrease in the PME level 
was observed [66, 67]. Study on breast cancer cell lines 
showed higher phosphocholine in malignant cell line 
compared to nonmalignant cell line [58]. It has been 
shown that in some cancers malignant progression is 
associated with a switch from GPC to PC [57]. Elevated 
level of both PC and GPC has been detected in pros-
tate cancer cells [68]. PME/PDE ratios predicted early 
response to chemotherapy in patients with soft tissue 
sarcomas [69]. In addition, 31P MRS studies have also 
showed that the ratio of PCr/Pi and NTP/Pi is correlated 
with the tumor oxygen level [70, 71].
Hyperpolarized MRI in cancer
Techniques using hyperpolarized 13C labeled pyruvate 
infusion to monitor increased glycolysis in cancer have 
the potential to improve the way MRI is used for detec-
tion and characterization of cancer. To date, 13C pyruvate 
has been the most widely used hyperpolarize substrate 
both in preclinical and clinical studies [72, 73]. Level of 
hyperpolarized [1–13C] lactate following intravenous 
injection of 13C pyruvate increases with cancer progres-
sion and reduces after therapy [74]. Flux of hypepolar-
ized13C between pyruvate and lactate has been used to 
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visualize prostate cancer [75]. Hyperpolarized 13C lac-
tate study in a transgenic prostate cancer mouse model 
showed that the hyperpolarized lactate level progres-
sively increased with cancer aggressiveness and corre-
lated significantly with histological grading [72]. Studies 
with lymphoma-bearing mice injected with hyperpolar-
ized [1–13C] pyruvate have shown lower rate of pyruvate 
to lactate conversion after onset of chemotherapy, which 
correlated with the amount of cell death caused by the 
chemotherapeutic drug [76].
Recently, hyperpolarized 13C glucose has been used to 
monitor the glycolytic flux in mouse lymphoma tumor 
model [77] (Fig.  1). Despite the short spin–lattice (T1) 
relaxation of carbon in glucose 13C lactate signal was 
measured within tumor, which decreases following 
chemotherapeutic drug treatment. In addition, signal 
from 6-phosphogluconate was detected which is gener-
ated through the PPP. However, sensitivity of detection of 
hyperpolarized 13C lactate with hyperpolarized 13C glu-
cose infusion was much lower than hyperpolarized 13C 
lactate detected following injection of hyperpolarized 
13C pyruvate. Nonetheless, this method could provide a 
new way to monitor the glycolytic flux and PPP activity 
in tumor.
In a recent study, it has been shown that the tissue 
pH can be mapped through hyperpolarized MRI [78]. 
Since many pathological changes are associated with pH 
changes, monitoring the pH in  vivo can provide useful 
information about the tissue pathological stage. The pH 
map can be generated noninvasively by targeting conver-
sion of the injected hyperpolarized 13C labeled bicarbo-
nate to hyperpolarized carbon dioxide in tumor tissues 
[78] (Fig.  2). The mapping of pH changes in tumor can 
be used as a marker for evaluating the treatment efficacy 
as well as in designing of the effective cancer treatment 
protocols.
In clinic, by using hyperpolarized technique the treat-
ment response can be monitored within hours, and based 
on the observation more effective treatment could be 
initiated.
Chemical exchange saturation transfer (CEST) imaging
Chemical exchange saturation transfer (CEST) is a new 
contrast enhancement technique that enables the indi-
rect detection of molecules and macromolecules possess-
ing exchangeable protons [79–81]. In CEST experiment, 
these exchangeable protons can be specifically saturated 
using frequency selective radiofrequency (RF) satura-
tion pulse which leads to the zero magnetization on these 
exchangeable protons, and their exchange with the bulk 
water protons decrease the bulk water signal [80, 81]. 
The decrease in bulk water signal can be quantified and 
mapped to provide high resolution images of specific 
molecules and macromolecules.
Imaging of mobile protein and peptide in cancer
Amide proton transfer (APT) imaging is one of the 
widely used CEST based methods which is being used 
to image mobile protein and peptides in cancers in vivo 
[82–86]. Briefly, APT imaging method depends on 
exchange between protons of free water and those of 
amide groups (–NH) of endogenous mobile proteins 
and peptides [87]. Higher numbers of such amide pro-
tons are reported in cancer compared to normal healthy 
tissue. APT imaging of the human brain tumor showed 
higher APT contrast in tumor region than contralateral 
normal brain parenchyma [83, 88–90]. It has been shown 
that APT can better discriminate tumor from edema and 
Fig. 1 Anatomical image is showing a subcutaneous EL4 tumor in a mouse model. Chemical-shift imaging for 13C-glucose and 13C-lactate from the 
same animal was obtained 15 s after intravenous injection of 0.4 mL of 200 mM hyperpolarized glucose. 13C-lactate signal demonstrates generation 
of lactate through anaerobic glycosylation. This material was reproduced with permission from the Nature Publishing Group and Rodrigues et al. 
[77]
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normal brain areas than conventional T2, T1 and FLAIR 
imaging [88]. APT imaging has been used to classify the 
tumors, which showed higher APT contrast in high grade 
tumor compared to low grade tumor [83] (Fig.  3). In a 
recent study, APT imaging has been used to distinguish 
tumor recurrence from radiation necrosis [89]. While 
the conventional methods cannot reliably differentiate 
between tumor recurrence and radiation necrosis, APT 
contrast was shown to be hyper-intense in tumor tissues 
and hypo-intense in necrotic areas (Fig. 4) [89]. APT was 
also used to evaluate the radiation treatment monitoring 
in cancer, which showed decreased APT contrast post 
radiation treatment [89]. 
Amide proton transfer weighted imaging has been also 
used to assess the early treatment response during short-
term chemotherapy with temozolomide (TMZ) in mouse 
model of glioblastoma multiforme (GBM), which showed 
decreased APT contrast following treatment, while in 
control non-treated group increased APT contrast is 
observed [90] (Fig.  5). The treated group showed low 
level of Ki67, an index of tumor cells proliferation, than 
nontreated control tumor (Fig. 5). In another experiment, 
TMZ-resistant GBM line showed increase in both APT 
signal and levels of Ki67 despite the same course of TMZ 
treatment [90]. Based on these observations it has been 
suggested that the APT signal may be useful in monitor-
ing the treatment response and to evaluate the tumor 
progression.
In a very recent study, APT was used to image ortho-
tropic lung tumor in mouse model and has showed 
higher APT contrast in tumor [84] (Fig. 6). It is presumed 
that APT can be used as a potential biomarker to char-
acterize and grade the lung cancer non-invasively in vivo. 
Applications of APT imaging are emerging in studies of 
other cancer types including breast cancer, prostate can-
cer, bladder cancer etc.
Fig. 2 pH mapping of tumor tissue. Anatomical image is showing a subcutaneously implanted EL4 tumor. The pH map generated by calculating 
the ratio of the hyperpolarized H13CO3 and 13CO2 voxel intensities using handersal-hasselbatch equation. Reproduced with permission from the 
Nature Publishing Group and Gallagher et al. [78]
Fig. 3 APT imaging of brain tumor (glioblastoma multiforme) in a human patient. Anatomical T2 weighted (a) and post contrast T1 weighted (b) 
images are showing diffuse tumor in parietal lobe. APT weighted image (c) shows high contrast in tumor than normal brain parenchyma. Immuno-
histochemical staining of Ki-67 (d) shows very high proliferative activity in tumor with high cellular density. Reproduced with permission from the 
Oxford University Press and Togao et al. [83]
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Treatment response to high intensity focused ultra-
sound (HIFU) in animal model of tumor has been moni-
tored through APT weighted imaging [91]. A decrease 
in APT contrast in tumor following HIFU treatment 
was observed, which was complementary to the gado-
linium (Gd) based study [91] (Fig. 7). This suggests that 
Fig. 4 Differentiation of radiation necrosis and glioma using APT MRI. MRI of radiation treated animals is performed after 178 days of 40 GY radia-
tion treatment. Radiation necrosis (black arrow) area as revealed by Gd enhancement shows hypointense to isointense on APT weighted image 
compared to contralateral brain tissue. While both SF188/V + (pink arrow) and 9L (red arrow) tumors show hyperintensity both on the Gd enhanced 
and APT-weighted images, which correspond to high cellularity. Reproduced with permission from the Nature Publishing Group and Zhou et al. [89]
Fig. 5 Monitoring TMZ treatment response in mouse model of human glioblastoma multiforme using APT contrast. APT weighted images are 
showing increased APT contrast in control animal than treated animal. Lower contrast in treated group corresponds to decreased tumor cells prolif-
eration. Reproduced with permission from the National Academy of Sciences and Sagiyama et al. [90]
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APT can effectively replace the Gd based monitoring 
of HIFU treatment response in cancer. Moreover, APT 
uses endogenous mobile proteins and peptides for sig-
nal measurement while in Gd based study exogenous 
administration of contrast is required. Despite plethora 
of applications, the physiological basis of APT and APT 
changes are still not well understood.
CEST imaging of small metabolites in tumor
Role of different biochemical signatures in cancer malig-
nancy is known since decades. Efforts have been made 
to quantify changes in these metabolites non-invasively 
using 1H MRS, which showed altered concentration of 
different metabolites in tumor tissue [26]. These metabo-
lites include glutamate, creatine, myo-inositol, glycine, 
etc. However, 1H MRS suffers from poor resolution and 
does not provide information regarding heterogeneous 
distribution of metabolites concentration in cancer tis-
sue. Recently, high resolution imaging of these metabo-
lites has been performed using CEST imaging [92–94]. 
However, changes in pH and other biological factors may 
affect the quantification of CEST contrast from these 
metabolites in cancer. Most of these metabolites present 
intracellular in cancer, and it is well known that the intra-
cellular pH in cancer mostly does not change, therefore, 
by using CEST method concentration changes of these 
metabolites in response to tumor aggressiveness can be 
quantified and may be used as a bio-marker to evaluate 
therapeutic responses.
Recently, glucose was used as exogenous CEST con-
trast agent to monitor the glucose CEST enhancement 
(GCE) in mouse model of colorectal cancers [95]. Higher 
GCE was observed in SW1222 than LS174T cancer 
(Fig.  8) [95]. Based on the findings, it was further sug-
gested that the GCE can be used to distinguish tumor 
types with differing phenotypic characteristics. Since 
glucose is not toxic and is readily available it can be 
rapidly used in clinic to evaluate the different types of 
cancers.
Alterations in mucin expression and glycosylation are 
associated with the cancer progression and invasion 
[96]. Very recently CEST technique has been used to 
differentiate the glycosylated mucin tumor from under-
glycosylated mucin tumor, and showed that the deglyco-
sylation of mucin resulted in more than 75 % reduction in 
CEST contrast [97] (Fig. 9).
CEST imaging of protease enzyme expression
Developing proteolytic enzyme inhibitors is an active 
area of research and the ability to non-invasively 
Fig. 6 APT imaging of lung tumors. Anatomical proton weighted image and APT-weighted images of A549 (a) and LLC (b) tumors in mouse model. 
Both the tumors showed higher APT contrast than surrounding tissues including spinal cord (white arrows) and skeletal muscles. Higher CEST con-
trast is detectable on LLC tumor than A549 tumor (black arrow). Reproduced with permission from Public Library of Science and Togao et al. [84]
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detect proteolytic enzyme activity would be valuable in 
selecting tumors for specific inhibitors and for detect-
ing response to such agents. MRI Studies have been 
performed to detect the transglutaminase [98] and 
Hyaluronidase [99] activity in preclinical setup using 
contrast generated by a peptide linked to GdDTPA. 
Recently, Haris et  al., have used GluCEST method to 
image the cathepsin protease activity in 9L tumor in 
rat model using poly-L-glutamate as a CEST imag-
ing probe [100] (Fig.  10). Cathepsin protease expres-
sions in tumor cleave the PLG into smaller fragments 
or its monomers and expose several glutamate amine 
protons, which can be monitored noninvasively using 
GluCEST technique. Since the elevated protease activ-
ity is highly associated with tumor malignancy [101], 
by monitoring the kinetics of poly-L-glutamate (PLG) 
cleavage tumor aggressiveness can be mapped. Fur-
ther, PLG has been used as a macromolecule for the 
targeted cancer drugs delivery [102], this method can 
be potentially used to monitor targeted drug delivery 
as well as their efficacy on tumor cells. This technique 
may also provide a novel diagnostic tool for early 
detection of tumors and in effective anti-cancerous 
drug designing.
Fig. 7 Monitoring HIFU treatment in cancer. Proton anatomical image, APT weighted image and GD contrast enhanced image show the changes 
in tumor following HIFU treatment. Decreased APT contrast following HIFU was observed which is comparable to the Gd based contrast enhance-
ment study. Reproduced with permission from John Wiley and Sons and Hectors et al. [91]
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CEST imaging of cancer tissue redox potential
Tumor redox potential is an important marker to predict 
the biological as well as metabolic processes in tumor 
cells [103]. The tumor redox state has been recently 
imaged through CEST MRI in two different breast cancer 
mouse xenograft models, and correlated with the redox 
measurement by optical imaging method [104] (Fig. 11). 
Cai et  al. have observed that the CEST contrast from 
tumor tissue linearly correlated with the Nicotinamide 
adenine dinucleotide (NADH) concentration as well as 
NADH redox state. Cai et al. [105] have further extended 
the CEST methods to characterize the prostate cancer 
in  vivo in preclinical mouse model. Significantly higher 
CEST contrast was observed in PC-3 than DU-145 pros-
tate cancer [105].
The above studies suggest that once validated, the 
CEST methods can be used in clinical setup to character-
ize tumor aggressiveness and to monitor the therapeutic 
responses in vivo.
MRI reporter genes in cancer
Gene expression in cancer cell can be monitored using 
reporter genes. Expression of reporter genes such as 
beta-galactosidase and luciferase has been examined 
Fig. 8 GluCEST imaging in mouse model of colorectal cancers (SW1222 than LS174T). SW1222 cancers show higher GluCEST contrast than LS174T 
cancers. Reproduced with permission from the Nature Publishing Group and Walker-Samuel et al. [95]
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ex  vivo using immunohistochemical and histological 
techniques. Though, ex vivo methods provide high speci-
ficity and sensitivity, they cannot provide dynamic infor-
mation, and require large number of animals to sacrifice 
for a longitudinal study. On the other hand, optical imag-
ing can provide some structural and functional informa-
tion about the gene expression in vivo but the sensitivity 
deteriorate very fast in the deeper part of tissue. These 
problems have been overcome by developing MR based 
reporter genes, which enable in vivo imaging of cell pro-
liferation and migration.
Magnetic resonance reporter genes have potential to 
monitor the transgene expression in  vivo noninvasively. 
These genes can be applied to interrogate the efficacy of 
gene therapy, to assess cellular differentiation, cell traf-
ficking, and specific metabolic activity, and also assess 
changes in the microenvironment [106]. Various MR 
reporter genes probes are generated to monitor the 
Fig. 9 Mucin dependent CEST contrast imaging. Underglycosylatedmucin 1 (uMUC1+) overexpressed in LS174T which shows significantly low 
CEST contrast compared to the U87 tumor which is devoid of mucin expression. Reproduced with permission from the Nature Publishing Group 
and Song et al. [97]
Fig. 10 CEST imaging of protease enzyme expression in cancer. a GluCEST map of 9L cancer cells cultured without PLG. b GluCEST map of 9L cell 
line cultured in the presence of PLG showed ~17 % increased GluCEST contrast compared to (a), which is due to the cleavage of PLG by CtB present 
in the tumor cells. c PLG solution in PBS does not show any appreciable GluCEST contrast. d Western blot analysis shows expression of cathepsin 
B in both mature and pro form while cathepsin L only in the pro form. The cleavage of PLG in this tumor cell line is predominantly due to CtB. e, f 
Anatomical image and GluCEST map from a rat brain with a 9L tumor. g At 60 min post intra-venous injection of PLG increased GluCEST contrast 
was observed in the tumor region due to cleavage of PLG possibly by proteases. Reproduced with permission from the Nature Publishing Group 
and Haris et al. [100]
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activity of different genes in biologic systems in  vivo. 
Reporter genes basically generated by fusing promoter 
from a gene of interest to the gene of either a easily 
detectable protein or an enzyme capable of generating 
detectable contrast agent upon reaction with its substrate 
(Fig. 12). Gene expression imaging has had a revolution-
ary impact on laboratory study of cancer biology and is 
likely to play an important role in clinical trials in the 
future.
Ferritin MR reporter gene has been used to track the 
metastatic melanoma cells in lymph node [107] (Fig. 13) 
and to image the C6 glioma tumor cells [108] in vivo in 
preclinical mouse model. The cancer cells expressing 
the human ferritin protein can be detected as low signal 
intensity both on T2 and T1 relaxation weighted images. 
The change in the T2 and T1 relaxation properties can be 
used to track cancer cells in vivo as well as to evaluate the 
therapeutic effect of different drugs on cancer cells. In 
one of the study, ferritin high chain (FHC) overexpress-
ing fibroblasts administered intraperitonealy in a mouse 
model of human ovarian cancer [109]. The recruitment 
of fibroblasts was monitored using R2 (1/T2) mapping of 
tumor which demonstrated high R2 value at the tumor 
rim compared to the tumor mouse which received con-
trol fibroblasts [109].
Arena et  al. [110] have used the Lac Z as an MRI 
reporter gene to image proliferation of mouse mela-
noma cells. The lac Z expressing tumor cells can be 
easily distinguished by exogenous administration of 
a gadolinium based contrast agent. This gadolinium 
based contrast was designed as such that it maintain 
gadolinium ion in a water inaccessible position until it 
cleaved by the β-galactosidase enzyme express by the 
Lac Z. The cleavage results in transition of Gd ion in a 
water accessible position which generate strong posi-
tive contrast on T1 weighted MRI. Cancer cells express-
ing the Lac Z provides higher contrast than control after 
exogenous administration of contrast agent. In another 
study, the interaction between β-gal and a staining salt 
Fig. 11 CEST imaging of breast cancer. CEST maps (at 2 and 3 ppm) of flank MDA-MB-231 and MCF-7 mice breast cancers models. NADH and 
NADH redox ratio show higher rim to core ratio of NADH concentration in MDA-MB-231 than MCF-7 tumor. Reproduced with permission from 
Springer and Cai et al. [104]
Fig. 12 Reporter gene imaging. Reporter gene inserted in the 
downstream of a gene promoter. The promotor activation transcribes 
reporter gene to reporter mRNA, which produces reporter protein 
after translation. The reporter protein converts the substrate or probe 
into active form which can be imaged using MRI
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i.e. 3,4-Cyclohexenoesculetin b-D-galactopyranoside in 
presence of ferric ions generated a strong hypointensity 
on T2* weighted image in tumor cells expressing LacZ 
[111] (Fig. 14).
With exception of ferritin all other MR reporter genes 
are rely on administration of substrate, which limits it’s 
access to all tissues. Poly-l-lysine ability to use as a CEST 
contrast provided the concept for the synthesis of an arti-
ficial gene rich in lysine residue [112]. The 9L rat glioma 
cells’ overexpressing this transgene is easily distinguished 
from the control 9L cells tumor (Fig. 15) [112].
Molecular MR imaging in cancer immunotherapy
Despite significant advances in chemotherapy and radio-
therapy, cancer treatment remains an immense challenge. 
Cell-based cancer immunotherapy is gaining widespread 
attention as it provides a novel approach to treat cancer 
by triggering the patients’ own immune system to induce 
a potent anti-tumor response. Various cell types, such as 
lymphocytes (CD4+ and CD8+ T cells), dendritic cells 
(DCs) and natural killer cells (NK cells) have shown their 
therapeutic efficacy to treat cancer patients. This pro-
vides a highly selective way to kill cancerous cells with 
significantly less side effects on normal cells.
Currently, the only way to monitor the bio-distribution 
and pharmacokinetics of these therapeutic cells is rely on 
immunohistochemistry of the excised tissues. Monitor-
ing delivery and therapeutic effect of these cells in  vivo 
non-invasively can make the difference in failure and suc-
cess to cancer immunotherapy. Non-invasive monitoring 
of the disposition, migration and destination of therapeu-
tic cells will facilitate the development of cell based ther-
apy. In general, response to immunotheryapy is mostly 
evaluated by monitoring alteration in tumor size, tumor 
markers and improved survival rates, which require sev-
eral weeks to months or even years for the treatment 
assessment. The localization of immune cells at the 
tumor site is an early marker for the treatment response, 
which is primarily examined through invasive histologic 
tissue analyses.
With the development in the molecular imaging tech-
nology it is possible to track the fate of these therapeu-
tic cells in  vivo non-invasively. Noninvasive molecular 
Fig. 13 In vivo imaging of metastatic cells expressing myc-tagged human ferritin heavy chain (myc-hFTH) in lymph nodes (LNs). T2* map of metas-
tasis from control and myc-hFTH cells in the left and right axillary (A) and brachial (B) LNs in nude mice. Reproduced with permission from John 
Wiley and Sons and Choi et al. [107]
Fig. 14 MRI detection of beta b-gal activity in MCF breast tumor 
transfected with lac Z. After intratumoral injection of S-Gal and ferric 
ammonium citrate, the tumor expressing lac Z shows strong hypoin-
tense contrast [111]. Reproduced with permission from John Wiley 
and Sons and Cui et al. [111]
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imaging has potential to provide instant assessment of 
cell based therapy in both clinical and preclinical settings. 
These immunotherapeutic cells can be modified as such 
so that they can be easily detectable by MRI by introduc-
ing imaging probes into cells or attaching them on cell 
surface before injection. The obtained imaging signals 
can potentially be used as biomarkers for tumor response 
and for differentiating patients who are responders or 
nonresponders to immunotherapy.
In a recent study, DCs have been directly labeled using 
19F, perfluoropolyether (PFPE) which can be visualized 
by MRI [113]. It is observed that PFPE have insignificant 
effect on DC function and moreover, by using 19F more 
selective images can be obtained as the background sig-
nal for 19F within tissues is negligible. With the advent 
of the iron oxide nano particles and their approval from 
FDA in clinical use open a new approach to detect the 
infiltrating immune cells to tumor cells in  vivo. Cells 
labelled with nanoparticles produce strong hypointense 
contrast on MRI and showed promise of direct clini-
cal translation. Sheu et al. [114] showed that tumor sig-
nal changes in T2* relaxation time maps generated from 
gradient echo sequences after intra-arterial infusion of 
SPIO-labeled NK-92cells.
To overcome the toxicity effect to normal cells, in a 
very recent approach cancer natural killer (NK) cells are 
genetically altered to recognize tumor associated surface 
antigens, which showed highly efficient toxicity against 
tumor cells with minimal or no effect on normal healthy 
cells. Different tumor associated antigens have been rec-
ognized as target for the NK cells- for example ErbB2/
HER2 receptor tyrosine kinase in breast and ovarian can-
cer cells, pan-carcinoma antigen epithelial cell adhesion 
molecule (EpCAM) in prostate cancer cell, and CD20 dif-
ferentiation antigen in B cell malignancies.
EpCAM-targeted and ferumoxide labeled NK cells 
demonstrated substantial decreased T2* signals in 
EpCAM-positive prostate cancers than ferumoxide 
labeled nontargeted parental NK-92 cells [115]. The 
relaxation maps R2* (R2* = 1/T2*) can be generated and 
used to quantify labeled cells in tumor and other tissues. 
Figure 16 is showing a T2*-weighted image and the cor-
responding R2* map of a Daudi Burkitt’s lymphoma in a 
mouse model before and 6 h post injection of ferumox-
tyol-labeled NK cells, which is depicting higher R2* signal 
in the tumor region [116]. MRI can provide a noninvasive 
and real-time immune cell tracking which may provide 
a surrogate marker for tumor response as early as 24  h 
after start of therapy.
Conclusions
Molecular MR imaging is well suited to measure molecu-
lar and cellular processes including metabolism, apop-
tosis, cell proliferation and biosynthetic pathways of 
different metabolites in vivo in cancer. Molecular imaging 
can play an important role in every aspect of oncology 
Fig. 15 Lysine rich protein (LRP) based MR reporter genes transfected with the 9L gliosarcoma cells before implantation in the rat brain. On 
anatomical imaging both the LRP and control xenografts show the similar signal intensity (a). The CEST map highlighted the LRP xenograft due to 
the expression of lysine rich protein, which can be easily detected through APT CEST (b). Reproduced with permission from the Nature Publishing 
Group and Gilad et al. [112]
Fig. 16 Tracking the NK cells in mouse model of Daudi Burkitt’s 
lymphoma. Axial T2*-weighted gradient echo images show the flank 
tumor (arrow). The corresponding R2* maps show increase in R2 sig-
nal 6 h post ferumoxytol-labeled NK cells injection. Reproduced with 
permission from Thomas Hill Publisher and Sta Maria et al. [116]
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practice, including early disease detection, diagnosis, 
staging, personalized treatment, and treatment monitor-
ing. Prostate, ovarian and lung cancer are just a few of the 
many types of cancer in which molecular imaging truly 
changed the direction and outcome of the patient care. 
The ability of molecular imaging to detect abnormalities 
very early in the progression of disease has the potential 
to change medicine from reactive to proactive, detecting 
and curing disease in its most treatable phase and sav-
ing countless lives. In medical setup, molecular MRI will 
pave the way toward a significant improvement in early 
detection of disease, therapy planning and monitoring 
the therapeutic outcomes.
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